CEO.CA's Inside the Boardroom: Cardiac MRI Alternative Gets FDA Nod - Ventripoint CEO on U.S. and China Sales Plans
Ventripoint Diagnostics (VPTDF) has achieved a significant milestone with FDA approval for its innovative heart ultrasound software technology. The company's solution transforms standard ultrasound machines into advanced diagnostic tools that rival MRI capabilities at a substantially lower cost.
CEO Hugh MacNaught announced a strategic pivot to a subscription-based business model, moving away from equipment sales. The company's technology offers heart scans at 5.5 times lower cost than traditional MRI in the US, while equipment costs are reduced to less than 10% of conventional MRI systems. Revenue generation is expected to commence before the end of the year as the company transitions from product development to commercialization.
Ventripoint Diagnostics (VPTDF) ha raggiunto una tappa importante con l'approvazione della FDA per la sua innovativa tecnologia software per ecografie cardiache. La soluzione dell'azienda trasforma ecografi standard in strumenti diagnostici avanzati comparabili alla risonanza magnetica a costi molto inferiori.
Il CEO Hugh MacNaught ha annunciato un cambio strategico verso un modello di business basato su abbonamento, abbandonando la vendita di apparecchiature. La tecnologia permette esami cardiaci a un costo 5,5 volte inferiore rispetto alla risonanza magnetica tradizionale negli USA, mentre il costo delle apparecchiature si riduce a meno del 10% rispetto ai sistemi MRI convenzionali. Si prevede che i ricavi inizieranno entro la fine dell'anno, man mano che l'azienda passerà dallo sviluppo del prodotto alla commercializzazione.
Ventripoint Diagnostics (VPTDF) ha alcanzado un hito importante con la aprobación de la FDA de su innovador software para ecografías cardiacas. La solución de la compañía convierte ecógrafos estándar en herramientas diagnósticas avanzadas comparables a la resonancia magnética a un coste sensiblemente menor.
El CEO Hugh MacNaught anunció un giro estratégico hacia un modelo de negocio basado en suscripción, abandonando la venta de equipos. La tecnología ofrece exploraciones cardíacas a un coste 5,5 veces inferior al de la resonancia magnética tradicional en Estados Unidos, mientras que el coste del equipo se reduce a menos del 10% de los sistemas de RM convencionales. Se espera que los ingresos comiencen antes de finalizar el año a medida que la compañía pase del desarrollo a la comercialización.
Ventripoint Diagnostics (VPTDF)는 혁신적인 심장 초음파 소프트웨어 기술에 대해 FDA 승인을 받아 중요한 이정표를 달성했습니다. 이 회사의 솔루션은 표준 초음파 장비를 MRI 수준의 진단 도구로 전환하면서도 훨씬 낮은 비용으로 제공합니다.
CEO Hugh MacNaught는 장비 판매에서 벗어나 구독 기반 비즈니스 모델로의 전략적 전환을 발표했습니다. 이 기술은 미국에서 기존 MRI보다 비용을 5.5배 낮춰 심장 스캔을 제공하며, 장비 비용은 기존 MRI 시스템의 10% 미만으로 줄어듭니다. 제품 개발에서 상업화로 전환함에 따라 연말 이전에 수익 창출이 시작될 것으로 예상됩니다.
Ventripoint Diagnostics (VPTDF) a franchi une étape majeure avec l'approbation par la FDA de sa technologie logicielle innovante pour l'échographie cardiaque. La solution transforme des appareils échographiques standards en outils diagnostiques avancés comparables à l'IRM, à un coût nettement inférieur.
Le PDG Hugh MacNaught a annoncé une réorientation stratégique vers un modèle commercial par abonnement, abandonnant la vente d'équipements. La technologie permet des examens cardiaques à un coût 5,5 fois inférieur à celui de l'IRM traditionnelle aux États-Unis, tandis que le coût des équipements est réduit à moins de 10% de celui des systèmes IRM conventionnels. Les revenus devraient commencer avant la fin de l'année, alors que l'entreprise passe du développement produit à la commercialisation.
Ventripoint Diagnostics (VPTDF) hat einen wichtigen Meilenstein erreicht: die FDA-Zulassung für seine innovative Ultraschall-Software für das Herz. Die Lösung des Unternehmens verwandelt Standard-Ultraschallgeräte in fortschrittliche Diagnosetools, die mit MRT vergleichbar sind – und das zu deutlich geringeren Kosten.
CEO Hugh MacNaught kündigte eine strategische Ausrichtung auf ein abonnementbasiertes Geschäftsmodell an und verabschiedete sich von Geräteverkäufen. Die Technologie ermöglicht Herzuntersuchungen zu einem 5,5-fach niedrigeren Preis als herkömmliche MRTs in den USA, während die Gerätekosten auf weniger als 10% herkömmlicher MRT-Systeme sinken. Es wird erwartet, dass die Umsatzgenerierung noch vor Jahresende beginnt, wenn das Unternehmen vom Produktentwicklungs- in den Kommerzialisierungsmodus übergeht.
- FDA approval received for heart ultrasound diagnostic software
- Technology reduces scan costs by 5.5x compared to traditional MRI
- Equipment costs less than 10% of conventional MRI systems
- Strategic shift to subscription model to enhance market adoption
- Revenue generation expected before year-end
- Transition from equipment sales to subscription model may impact short-term revenue
- Will need to compete with established MRI providers in the market
Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.
Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.
Meet the Executive Shaping the Biotechnology Landscape
'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.
Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC Pink: VPTDF) has created software that turns regular heart ultrasound machines into powerful diagnostic tools rivaling expensive MRI scanners - but at a fraction of the cost and without the hassle of multiple appointments. CEO Hugh MacNaught explains how after getting FDA approval, the company is changing its entire business approach from selling equipment to offering monthly subscriptions, making it easier for doctors to adopt the technology. The numbers are compelling: heart scans cost 5.5 times less than MRI in the US, while equipment costs drop to under
Ventripoint Diagnostics
(TSXV: VPT) (OTC Pink: VPTDF)
Cannot view this video? Visit:
https://www.youtube.com/watch?v=qTE_ImB8RoQ
Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.
Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ceo.ca for further details and opportunities.
About CEO.CA
The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.
CEO.CA is a wholly owned subsidiary of EarthLabs, Inc.
For further information please contact:
CEO.CA
Email: hello@ceo.ca
Website: CEO.CA
Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262180
FAQ
What FDA approval did Ventripoint Diagnostics (VPTDF) receive in 2025?
How much cheaper are Ventripoint's heart scans compared to traditional MRI?
What is Ventripoint's new business model for 2025?
When does Ventripoint (VPTDF) expect to generate revenue from its new business model?
How much do Ventripoint's systems cost compared to traditional MRI equipment?
